CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
employment-based reinforcementbehavioral
Likely dose
Not stated in record
Key inclusion· 7
  • Age 18-65 years
  • Unemployed: no work in past 30 days and earning ≤$200/month in taxable income
  • Injection drug use history with visible track marks
  • Urine positive for both opiates and cocaine at entry
Key exclusion· 9
  • Active hallucinations, delusions, or thought disorder
  • Imminent threat to harm self or others
  • Currently incarcerated, in halfway house, or under constant monitoring
  • Pregnant or breastfeeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00149669
NCT00149669N/ACompleted

Employment-Based Addiction Pharmacotherapy

Johns Hopkins University·interventional·Posted Sep 8, 2005·Updated Sep 14, 2017

In Brief

A clinical study evaluating employment-based reinforcement for Cocaine-Related Disorders and 3 related conditions. Completed, enrolled 67 participants across 1 site.

Detailed Summary

A randomized study is planned over 5 years to evaluate the effectiveness of the Therapeutic Workplace in promoting naltrexone ingestion and abstinence in unemployed opiate-dependent injection drug users. Participants will be offered an opioid detoxification and naltrexone induction. Participants who complete the naltrexone induction will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and prescribed naltrexone for 26 weeks. The groups will differ in the contingencies imposed to work and earn salary. Work Plus Naltrexone Contingency participants will be required to ingest naltrexone to work, and will receive a brief pay decrease for missing a dose. Work Plus Naltrexone Prescription participants will be prescribed naltrexone, but will not be required to ingest it to work. This study will provide a rigorous evaluation of a novel employment-based intervention, the Therapeutic Workplace, to promote naltrexone ingestion and drug abstinence in a population of injection drug users who are at considerable risk of spreading or contracting HIV infection. Hypotheses being tested in this study are: Naltrexone ingestion will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package. Opiate abstinence will be maintained in the group exposed to the employment-based naltrexone treatment significantly more than the group exposed to usual-care treatment package.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 20.8 years ago

Interventions

employment-based reinforcementbehavioral

Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.